Abstract
The safety, toxicity and pharmacokinetics of nevirapine were studied in HIV-infected pregnant women beginning chronic therapy late in the third trimester and in their infants. Initial dose pharmacokinetic profiles in the pregnant women were similar to those seen in nonpregnant adults. Serum nevirapine concentrations fell below the 100-ng/ml target concentration by Day 7 of life in four infants, suggesting that nevirapine elimination is accelerated in these infants compared with newborns whose mothers receive only a single intrapartum nevirapine dose.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / adverse effects
-
Anti-HIV Agents / pharmacokinetics*
-
Female
-
HIV Infections / drug therapy*
-
HIV-1*
-
Humans
-
Infant, Newborn
-
Infectious Disease Transmission, Vertical / prevention & control
-
Nevirapine / administration & dosage
-
Nevirapine / adverse effects
-
Nevirapine / pharmacokinetics*
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy*
-
Pregnancy Complications, Infectious / virology
Substances
-
Anti-HIV Agents
-
Nevirapine